Social prescribing program to improve patients’ quality of life, well-being did not prove effective

A social prescribing initiative, designed to improve patients' well-being and quality of life by connecting them to non-medical resources, did not prove effective overall. The study assessed the efficacy of a Scottish government-funded program that was developed to target social determinants of health among some of the most socioeconomically vulnerable adults in Glasgow. In the program, "Community-Links Practitioners" connected adult patients with community resources like exercise groups and drug and alcohol management support.

The study evaluated the health-related quality of life, at baseline and after nine months, of 288 adults enrolled in the program. The authors compared their scores with 612 non-matched adults in comparison general practices and found no significant benefit in the intervention group. In a subgroup analysis, those who visited the practitioner three or more times showed improved quality of life, but many who enrolled did not fully utilize the program. The findings of this study call into question the effectiveness of such social prescribing programs for improving short-term health-related quality of life. Discovering ways to improve the uptake and engagement rates of the intervention may lead to better overall outcomes.

Source:
Journal reference:

Mercer, S.W., et al. (2019) Effectiveness of Community-Links Practitioners in Areas of High Socioeconomic Deprivation. Annals of Family Medicine. doi.org/10.1370/afm.2429.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Phase 2 study evaluates safety and efficacy of asunercept in COVID-19 patients